Prostate cancer incidence, mortality, total and free prostate specific antigen

Hellenic Journal of Nuclear Medicine

Volumn 12, Issue 2, 2009, Pages

  Bantis, Athanasios ^a   Vasiliou, Olga ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

fPSA; Incidence of prostate cancer; Mortality; Prostate cancer in Greece; Total PSA

Indexed keywords

ANDROGEN; ESTROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER STAGING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; HORMONAL THERAPY; HUMAN; LUNG EMBOLISM; MULTICENTER STUDY; ORCHIECTOMY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW;

GREECE; HUMANS; INCIDENCE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 69249162095     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Eble J, Sauter G, Epstein J. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press 2004; 30-32.
2. Wingo PA, Landis S, Ries LA. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 1997; 47:239-242.
3. Mettlin CJ. Cancer epidemiology 50 years later. Cancer 1998; 183: 1275-1277.
4. Micheli A, Mugno E, Krogh V et al. Cancer prevalence in European registry areas. Ann Oncol 2002; 13:840-865. (Pubitemid 34752680)
5. Parkin DM, Bray F, Ferlay J et al. Cancer Incidence, Mortality and Prevalence Worldwide, GLOBOCAN 2002, American Cancer Society. Cancer J Clin 2005; 55:74-108.
6. Dimopoulos K. Urology in: Neoplasia of the prostate. Fifth edn. Paschalidis Publishing Co., Athens 1998; 379-402.
7. Bouchardy C, Fioretta G, Rapiti E et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008; 123:421-429. (Pubitemid 351842029)
8. Stamatiou K, Delakas D, Sofras F et al. Mediterranean diet, monounsaturated: saturated fat ratio and low prostate cancer risk. A myth or a reality. Minerva Urol Nefrol 2007; 59:59-66. (Pubitemid 46972173)
9. Simopoulos AP. The traditional diet of Greece and cancer. Eur J Cancer Prev 2004; 13:219-230.
10. Lilja H. Biology of prostate-specific antigen. Urology 2003; 62 (5suppl): 27-33.
11. Stephen JJ. Current Clinical Urology. In: Prostate Biopsy Indications Techniques and complications. Humana Press Totowa NJ. 2008; 29-40.
12. Carter HB, Kettermann A, Ferrucci L et al. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 2007;4:685-690. (Pubitemid 350030209)
13. Morris DL, Dillon PW, Very DL et al. Bayer immuno-1 PSA assay: automated, ultra sensitive method to quantitate total PSA in serum. J Clin Lab Anal 1998; 12:65-74.
14. Brawer MD, Mayer GE, Letran JL et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52:372-378.
15. Mitchell ID, Croal BL, Dickie A et al. A prospective study to evaluate the role of complexed PSA and freeZtotal PSA ratio for the diagnosis of prostate cancer. J Urol 2001; 165:1549-1553.
16. Elder JS, Catalona WJ. Management of newly metastatic carcinoma of the prostate. Urol Clin North Am 1984; 11:283-295. (Pubitemid 14123128)
17. Stamatiou K, Alevizos A, Mariolis A et al. Do clinically insignificant tumours of the prostate exist? Urol Int 2008; 81:379-382.
18. Moutzouris G, Barbatis C, Plasitiaris D et al. Incidence and histological findings of unsuspected prostatic adenocarcinoma in radical cystoprostatectomy for transitional cell cancer of the bladder. Scand J Urol Nephrol 1999; 33:27-30. (Pubitemid 29359280)
19. Bantis A, Zissimopoulos A, Kalaytzis C et al. Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia. Hell J Nucl Med 2007; 10:138-143. (Pubitemid 47337612)
20. DeCastro BJ, Baker KC et al. Effect of flexible cystoscopy on serum prostate-specific antigen values. Urology 2009; 73:237-240.
21. Freedland SJ, Kane CJ, Presti JC Jr et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol 2003; 169:969-973. (Pubitemid 36188136)
22. Ercole CJ, Lange PH, Mathisen M et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987; 138:1181-1184. (Pubitemid 17157542)
23. Killian CS, Yang N, Emrich LJ et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985; 45:886-891. (Pubitemid 15161096)
24. Bantis A, Zissimopoulos A, Kalaitzis C. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment. Hell J Nucl Med 2008; 11:21-25. (Pubitemid 351649753)
25. Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003; 8:259-269. (Pubitemid 36648812)
26. Miller MC, O'Dowd GJ, Partin AW et al. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer. Urol 2001; 57:1105-1111.
27. Stephenson RA. Prostate cancer trends in the era of PSA. Urol Clin North Am 2002; 29:173-181.
28. Partin AW, Brawer MK. Complexed PSA and calculated percent free PSA improves specificity for prostate cancer detection. J Urol 2003; 170:1787-1791.
29. Ellison L, Cheli CD, Bright S et al. Cost-benefit analysis of total free/total and complexed PSA for cancer screening. Urology 2002; 60(suppl 4A): 42-46.
30. Martin B, Cheli CD, Lifsey D et al. Complexed PSA performance for prostate cancer detection in an African American population. Urology 2003; 62; 835-839. (Pubitemid 37421227)
31. Carter HB, Ferrucci L, Kettermann A et al. Detection of life-threatening prostate cancer with PSA velocity during a window of curability. J Nat Cancer Institute 2006; 98:1521-1527. (Pubitemid 44680903)
32. Habib FK, Lee IR. Androgens levels in the plasma and prostatic tissues of patients with BPH and carcinoma of the prostate. J Endocr 1976;71:99-107.
33. Armstrong B, Doll R et al. Environmental factors and cancers incidence and mortality in different countries with special reference to dietary practices. Int J Cancer 1975; 15:617-631.
34. Rose DP, Boyar AP, Wynder EL et al. International comparisons of mortality rates for cancer of the breast, ovary, breast, prostate and colon, and per capita food consumption. Cancer 1986; 58: 2363-2371.
35. Schalken J. Androgen receptor mediated growth of prostate cancer. Eur Urol 2005; 4(8): Suppl. 4-11. (Pubitemid 41423587)
36. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate. Urology 2003; 62:11-20.
37. Denmeade SR, Lin XS, lssacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-265.
38. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993; 2:27-32.
39. Tombal B, Berges R. How good do current LHRH agonists control testosterone? Can this improved with Eligard? Eur Urol 2005; 49(8): Suppl. 30-36.
40. Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989; 33:45-52.
41. Lunglmayr G, Girsch E, Meixner EM et al. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urol Res 1988; 16:315-319. (Pubitemid 18204754)
42. Thompson IM, Goodman PJ, Tangen CM et al.The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224. (Pubitemid 36859473)
43. Bantis A, Zissimopoulos A, Athanasiadou P et al. Serum testosterone, dihydro-testosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adeno-carcinoma who underwent radical prostatectomy. Radio-immunoassays measurements. Hell J Nucl Med 2007; 10:56-61. (Pubitemid 46692253)
44. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164:726-729. (Pubitemid 30637611)
45. Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. Urology 2003; 169:517-523.
46. Catalona WJ. Informed consent for prostate-specific antigen screening. Urology 2003; 61:17-19. (Pubitemid 36151704)
47. Catalona WJ, Smith DS, Ratliff TJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl J Med 1991; 324:1156-1160.
48. Babaian RJ, Miyashita H, Evans RB et al. Early detection program for prostate cancer: results and identification of high-risk patient population. Urology 1991; 37:193-198.
49. Perlmutter MA, Lepor H. androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007; 9: S3-S8.
50. Khan MA, Partin AW. Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003; 8:259-269. (Pubitemid 36648812)
51. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332-353. (Pubitemid 39571710)
52. Crawford ED, Blumenstein BA, Goodman PJ et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990; 66:1039-1044. (Pubitemid 20293003)
53. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79:235-246.